Predictmedix AI Inc - 2025 Year End Corporate Update

Executive Summary

• Predictmedix AI reports a disciplined 2025 execution across technology development, global investor engagement, and strategic growth, positioning the company for accelerated expansion in 2026.
• Over 500,000 real‑world health scans were completed with SmartHealth AI Stations, validating scalability and commercial readiness of its core AI engine.
• The Company will issue 12.3 million common shares to nine consultants to align key advisors with long‑term value creation.

Key Details

• Technology Advancement: Hybrid quantum‑classical algorithms delivered sharper noise reduction, improved signal clarity, and higher screening accuracy on standard hardware.
• SmartHealth AI Stations: >500,000 scans performed in 2025, demonstrating robustness across diverse lighting conditions, skin tones, and occlusions; generated high‑value real‑world data for model training.
• Investor Relations: European roadshow held in Hungary, Croatia, Serbia; presentation at MK Investment Conference (Munich) increased institutional awareness and interest.
• Multi‑Vertical Growth Strategy: Continued focus on three verticals—SmartHealth stations, Clinical‑Trial AI platforms, Consumer mobile health apps—leveraging a unified Core AI Engine and shared datasets.
• Strategic Advisor Compensation: Plan to issue 12.3 million common shares to nine consultants; aligns contributors with long‑term shareholder interests and supports technology development.
• 2026 Outlook Priorities:
• Global scaling of SmartHealth deployments
• Expansion of mobile digital health solutions
• Accelerated U.S. and international commercialization
• Growth of recurring revenue streams across AI platforms
• Further integration of quantum‑inspired computation to improve signal fidelity, reduce bias, and enhance screening confidence.

Notable Quotes

• “Predictmedix AI is positioned to build on validated platforms, expanding datasets, and growing commercial traction while advancing quantum‑inspired AI capabilities across its health screening ecosystem.” – Dr. Rahul Kushwah, COO

Materiality Assessment: Non‑Material – Positive (company provides operational and strategic updates without new earnings or financing disclosures).